In the medically managed cohort , @-year primary outcome ( cardiovascular death , myocardial infarction , stroke , recurrent ischaemia with rehospitalization , urgent coronary revascularization ) event rates were @ % with vorapaxar and @ % with placebo ( HR @ , @ % CI @-@ @ ) , with no interaction between drug and management strategy ( p = @ ) .